Hemato-Oncology Daily Report: 01/24/2024

A phase I dose-finding study investigated the safety of a combination of venetoclax, bendamustine, rituximab, and ibrutinib in patients with relapsed/refractory mantle cell lymphoma and found that the regimen led to an overall and complete response rate of 80% (8/10) (1). The study reported hematologic toxicity as a significant complication, with thrombocytopenia being the most common adverse event. The dose level 1 included bendamustine 90 mg/m2 on days 1-2, rituximab 375 mg/m2 on day 1, ibrutinib 560 mg daily, and venetoclax 400 mg starting in cycle 2 for 5 days, demonstrating preliminary tolerability and efficacy.

Reference

Grieve C, Joseph A, Drullinsky P, Zelenetz AD, Hamlin P, Kumar A. Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma. Leuk Lymphoma. 2024 Feb;65(2):235-241. doi: 10.1080/10428194.2023.2283393. Epub 2024 Jan 24. PMID: 38264906.